NCT01313520已完成2 期
A Randomized Clinical Trial to Study the Effects of Infliximab on Clinical Efficacy and Hand and Wrist Magnetic Resonance Imaging (MRI) in Patients With Active Rheumatoid Arthritis (RA)(Protocol No. P08136)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 61
- 主要终点
- Change From Baseline in the Volume Transfer Rate From the Blood Plasma to the Enhancing Synovium (Ktrans)
研究概览
简要总结
This is a study to compare the effect of infliximab versus placebo on synovial inflammation as measured by dynamic contrast enhanced (DCE)-MRI of one wrist. The primary hypothesis is that over 14 weeks of therapy, the change from baseline in the volume transfer rate in enhancing synovium is larger due to treatment with infliximab than with placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have a clinical diagnosis of rheumatoid arthritis for at least 6 months
- •Must have at least 6 tender joints AND 6 swollen joints
- •Has a C-reactive protein ≥ 1.0 mg/L OR Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/hr
- •Baseline MRI must show evidence of synovitis in the wrist
- •Must have screening laboratory tests within acceptable levels
- •Women of childbearing potential and all men must agree to use a medically accepted method of contraception prior to entering the study and continue throughout study up to 6 weeks after study completion
- •Must meet tuberculosis (TB) screening criteria
- •Have received methotrexate therapy for ≥ 3 months; dose must be stable for at least 8 weeks
- •If taking the a disease modifying anti-rheumatic drug (DMARD) in combination with methotrexate must be on a stable dose
- •Must have a clinically acceptable 12 lead electrocardiogram (ECG)
- •If taking oral corticosteroids must be on a stable dose equivalent to ≤10 mg of prednisone (or prednisolone) per day for ≥2 weeks
- •If taking daily non-steroidal anti-inflammatory drug (NSAID) must be on a stable dose for ≥2 weeks; if taking NSAID on an as-needed basis must agree to discontinue use for at least 3 days and use only acetaminophen for breakthrough pain for 3 days before each MRI and clinic visit
- •If received biological therapies, the last dose of these drugs was to be received ≥ 3 months prior to the baseline visit AND the reason for discontinuations was not for safety considerations OR lack of efficacy
排除标准
- •Are pregnant, intend to become pregnant, or are breastfeeding
- •Has inflammatory arthritis other than RA
- •Has uncontrolled hypertension
- •Has moderate or severe congestive heart failure
- •Has a history of or current signs and/or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral, or psychiatric disease
- •Has a history of demyelinating disease or symptoms suggestive of multiple sclerosis or optic neuritis
- •Is currently participating in another clinical study or have participated in a clinical study (e.g., laboratory or clinical evaluation) within 4 weeks
- •Has history of any tumor with the exception of adequately treated basal cell carcinoma or carcinoma in situ of the cervix
- •Has a history of any latent or active granulomatous infection including histoplasmosis, or coccidiomycosis
- •Had a non-tuberculous mycobacterial infection or opportunistic infection (e.g. cytomegalovirus, Pneumocystis carinii, aspergillosis) within 6 months
- •Has a history of an infected joint prosthesis which has not been removed or replaced
- •Has a known hypersensitivity to human immunoglobulin proteins or other components of infliximab
- •Has received rituximab or natalizumab
- •Has known claustrophobia or other contraindication to MRI
- •Does not meet washout period guidelines for previous treatments/injections/vaccinations
研究组 & 干预措施
Infliximab
Experimental
3 mg/kg of Infliximab intravenous infusion
干预措施: Infliximab (Drug)
Placebo
Placebo Comparator
saline via intravenous infusion
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in the Volume Transfer Rate From the Blood Plasma to the Enhancing Synovium (Ktrans)
时间窗: Baseline and week 14
Dynamic Contrast Enhanced (DCE) Magnetic Resonance Imaging (MRI) was performed on one hand at baseline, and then at treatment week 14 to measure the rate constant of transfer of contrast (Ktrans).
次要结局
- Percentage of Responders With a 20% Improvement From Baseline in American College of Rheumatology (ACR) Responder Criteria for Tender and Swollen Joints (ACR20).(Baseline and week 14)
- Percentage of Responders With a 50% Improvement From Baseline in American College of Rheumatology (ACR) Responder Criteria for Tender and Swollen Joints (ACR50).(Baseline and week 14)
- Change From Baseline in Standardized Z-scores of Composite Endpoint Consisting of Clinical Disease Activity Measure DAS28 CRP + Ktrans.(Baseline and Week 14)
- Change From Baseline in Standardized Z-scores of Composite Endpoint Consisting of Clinical Disease Activity Measure DAS28 CRP + Rheumatoid Arthritis MRI Score (RAMRIS) Synovitis + RAMRIS Osteitis.(Baseline and Week 14)
研究者
相似试验
Unknown
4 期
Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRIRheumatoid ArthritisNCT01893151Jiangsu Simcere Pharmaceutical Co., Ltd.200
已完成
4 期
Treatment Of Knee Osteoarthritis With Intra-Articular InfliximabOsteoarthritis of the KneeNCT01144143Herbert Lindsley, MD16
已完成
3 期
Infliximab Plus Methotrexate for the Treatment of Rheumatoid ArthritisRheumatoid ArthritisNCT00269867Centocor, Inc.428
终止
2 期
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell ArteritisGiant Cell ArteritisNCT00076726Centocor, Inc.44
已完成
2 期
Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From CachexiaCOPDCachexiaNCT00244192Center for Integrated Rehabilitation and Organ Failure Horn16